Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H5N1 Vaccine in Healthy Adults
NCT00296634Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2006
- Primary completion
- Dec 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Inactivated Influenza A/H5N1 Vaccine in Avian influenza H5N1 (H5N1) (8 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Adverse event (AE) or serious adverse event (SAE) information at Day 208, Proportion of subjects achieving a serum neutralizing antibody titer >= 1:40 at Day 56 and 3 more. Started Mar 2006; status: completed.
02
Drugs
Inactivated Influenza A/H5N1 Vaccine
03
Conditions
Avian influenza H5N1 (H5N1)
Beyond the preview
Go deeper on NCT00296634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00296634.